On October 16, PHARMARON rose 3.33% intraday in Regular Trading, trading at HK$28.16, with turnover of HK$8.88 million.
The clearest recent catalyst is the company’s disclosure that Pharmaron Holdings Limited, an acting-in-concert party of the actual controllers, completed the placement of 18.373 million A shares, or 1.00% of total share capital, at RMB38.89 per share for total proceeds of about RMB715 million.
The transaction was placed to 13 institutional investors and had previously been priced at a roughly 6.96% discount to the October 12 A-share close, which had weighed on sentiment earlier in the week. With the transfer now completed, Pharmaron Holdings Limited’s stake fell from 9.82% to 8.82%, while the combined holdings of the three actual controllers declined from 17.52% to 16.52%. The completion may signal that the immediate supply overhang tied to the block sale has been absorbed.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments